Results 31 to 40 of about 16,194 (165)

Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology, 2015
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert, Ryan B, Perumpail, Aijaz, Ahmed   +2 more
openaire   +2 more sources

Mortality associated with the treatment of HCV with direct-acting antivirals [PDF]

Gut, 2017
We read with interest the study by Welzel et al 1 confirming the high efficacy of oral direct-acting antiviral agents (DAAs) for the treatment of chronic HCV infection.2 Results about safety are less clear, since in these patients who have a high risk of hepatic decompensation or death within 12 months, the rate of death was 7.8% during treatment and ...
Anne, Laurain, Laura, Kramer, Philippe, Sultanik, Anaïs, Vallet-Pichard, Philippe, Sogni, Stanislas, Pol   +5 more
openaire   +2 more sources

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Annals of Hepatology, 2017
Introduction: Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to ...
Curtis L. Cooper, Holly Hatashita, Daniel J. Corsi, Parmvir Parmar, Raymond Corrin, Gary Garber   +5 more
doaj   +1 more source

Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia

International Journal of Infectious Diseases, 2021
Objectives: Due to limited hepatitis C virus (HCV) sequence availability from patients in Russia, the relationship between subtypes and baseline resistance-associated substitutions (RAS) to direct antiretroviral treatment outcome is not fully understood.
Vasily Isakov, Charlotte Hedskog, Joel O. Wertheim, Reilly E. Hostager, Bandita Parhy, Adriano De Bernardi Schneider, Vithika Suri, Hongmei Mo, Natalia Geivandova, Vyacheslav Morozov, Elena Bessonova, Natalya Gankina, Konstantin Zhdanov, Dzhamal Abdurakhmanov, Evguenia Svarovskaia   +14 more
doaj   +1 more source

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States

Preventive Medicine Reports, 2023
The likelihood of clinicians prescribing direct-acting antiviral (DAA) therapy for patients with chronic hepatitis C virus (HCV) and substance use disorder (SUD) was assessed via a survey emailed throughout the United States to clinicians (physicians and
Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernández-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera, Robert L. Cook   +10 more
doaj   +1 more source

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

Efficacy and Mechanism Evaluation, 2021
Background: High cure rates with licensed durations of therapy for chronic hepatitis C virus suggest that many patients are overtreated. New strategies in individuals who find it challenging to adhere to standard treatment courses could significantly ...
Graham S Cooke, Sarah Pett, Leanne McCabe, Christopher Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chin Lye Ch’Ng, Benjamin Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, M Azim Ansari, Helen Ainscough, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker, the STOP-HCV trial team   +26 more
doaj   +1 more source

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy [PDF]

Clinical and Molecular Hepatology, 2020
The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs.
Chung-Feng Huang, Ming-Lung Yu
doaj   +1 more source

Direct-Acting Antiviral Agents and the Path to Interferon Independence [PDF]

Clinical Gastroenterology and Hepatology, 2014
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies.
Warren N, Schmidt, David R, Nelson, Jean-Michel, Pawlotsky, Kenneth E, Sherman, David L, Thomas, Raymond T, Chung   +5 more
openaire   +2 more sources

The ‘Viennese epidemic’ of acute HCV in the era of direct-acting antivirals

Journal of Hepatology, 2022
AbstractThe recently reported epidemic of acute hepatitis C virus (HCV) infections —observed predominantly among men who have sex with men (MSM)—may now decline due to wide availability of direct‐acting antivirals (DAAs). This study aimed to investigate the current trends of acute hepatitis C in Vienna.
David Chromy, David J. M. Bauer, Benedikt Simbrunner, Matthias Jachs, Lukas Hartl, Philipp Schwabl, Caroline Schwarz, Armin Rieger, Katharina Grabmeier‐Pfistershammer, Michael Trauner, Peter Ferenci, Mattias Mandorfer, Michael Gschwantler, Thomas Reiberger   +13 more
openaire   +2 more sources

Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals

Central European Journal of Immunology, 2021
Chronic hepatitis C (CHC) affects the activity of natural killer (NK) cells, but successful interferon- free treatment partially restores it. The goal of this study was to assess whether gender influences NK functionality.
Agata Zientarska, Justyna Mikuła-Pietrasik, Mariusz Kaczmarek, Aleksandra Witkowska, Błażej Rozpłochowski, Arleta Kowala-Piaskowska, Krzysztof Książek, Jan Żeromski, Iwona Mozer-Lisewska   +8 more
doaj   +1 more source